H.C. Wainwright raised the firm’s price target on Microbot Medical (MBOT) to $9 from $7 and keeps a Buy rating on the shares. The firm believes Liberty could outcompete large and expensive capital equipment while reducing radiation exposure as well as physical strain for healthcare providers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBOT: